secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001753926-23-000298
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical subsidiary Cortigent files for IPO; Vivani to fund ops until offering
--------------------------------------------------------------------------------

- Cortigent, Vivani's neuromodulation subsidiary, filed S-1 for IPO; ThinkEquity sole book-runner.
- Vivani agrees to fund Cortigent salaries, rent, overhead until Dec 31, 2024 or IPO close.
- Cortigent must repay all advanced funds plus accrued interest after funding support term.
- Cortigent will be controlled by Vivani post-IPO, led by CEO Jonathan Adams.
- IPO subject to market conditions; no assurance of completion or terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392623000298/0001753926-23-000298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392623000298/g083455_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-23-000298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer